Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis

Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis

Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepatic venous pressure (WHVP) and the free hepatic vein pressure (FHVP)- has been the criterion standard to determine portal pressure. Antiviral therapy may decrease HVPG which needs to be verified.

Inclusion Criteria:

• Patients with viral cirrhosis were diagnosed;
• Age 18-80 years;
• Need and willing to accept measure HVPG;
• First HVPG measurement of more than 5 mmHg;
• Signed Informed Consent

Exclusion Criteria:

• Patients with viral cirrhosis have been treated with antiviral therapy and have achieved virological response;
• Ready to accept or have accepted a TIPS procedure;
• Splenic embolization was performed;
• Inaccurate measurement of HVPG due to combined hepatic venous shunt;
• Complicated with alcoholic liver disease, autoimmune liver disease or other types of liver disease;
• Complicated with liver cancer or other organ malignancy;
• Combined with severe cardiopulmonary disease affects survival;
• Complicated with severe renal insufficiency;
• Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis;
• Women who are planning to become pregnant or who are pregnant or breastfeeding.